Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: May 17, 2013

NEW YORK (GenomeWeb News) – Kevin Hrusovsky is resigning his post at PerkinElmer as senior VP and president of the Life Science and Technology division.

Hrusovsky will serve as a consultant to the company for up to one year, beginning in June.

Hrusovsky came to PerkinElmer through the company's acquisition of Caliper Life Sciences, where he was CEO and president.

RainDance Technologies this week said that Jay Therrien, Roger Schaller, and Yafei Liu have joined the company to further accelerate growth in the digital PCR and targeted sequencing markets.

Therrien joins RainDance as vice president of worldwide sales. He was previously senior vice president of global sales at Knome. Prior to that, he was vice president of commercial operations and sequencing at Life Technologies, and he has also worked in various sales roles at Illumina.

Schaller will serve as RainDance's business leader for next-generation sequencing. He joins the company from Affymetrix, where he was senior director of business development for molecular diagnostics. Previously, he was director of North American sales and marketing at Cepheid, and he has also served in various business development, sales, and marketing positions at Dade-Behring.

And Liu joins RainDance as head of commercial operations for the Asia-Pacific region. Prior to RainDance, he was responsible for Life Tech's China sales team selling digital PCR, sequencing, and quantitative PCR products. Liu also previously worked at Applied Biosystems before it was acquired by Life Tech.

Steven Chu, the former Obama Administration energy secretary, has returned to Stanford University to continue pursuing his research as a professor of physics and molecular and cellular physiology, Stanford said this week.

During his stint running the Department of Energy, Chu launched the Advanced Research Projects Agency-Energy program, the Energy Innovation Hubs, and the Clean Energy Ministerial effort.

Before he went to DOE, Chu was director of the Lawrence Berkeley National Laboratory and a professor of at the University of California, Berkeley, and prior to that he was a professor at Stanford. Chu was a co-recipient of the Nobel Prize in Physics in 1997.

Harvard Bioscience said this week that company CEO and Director Chane Graziano has retired and resigned from the firm, and that the board of directors has appointed David Green to be interim CEO.

Graziano is retiring after 17 years as CEO at Harvard Bio and 49 years in the industry. The company said it will immediately begin a search for a new CEO.

Affymetrix shareholders have voted to re-elect 7 members of its board of directors, including Stephen Fodor; Frank Witney; Nelson Chan; Gary Guthart; Jami Nachtsheim; Robert Trice, and Robert Wayman. The firm's independent directors also elected Nachtsheim to be the board's lead director

Sanford-Burnham Medical Research Institute said this week it has recruited László Nagy to be a professor and program director in its Diabetes Obesity Research Center.

Currently, Nagy is head of the Center for Clinical Genomics and Personalized Medicine at the University of Debrecen Medical and Health Science in Hungary. He will join Sanford-Burnham in October.

Waters shareholders have re-elected the firm's board of directors, including Douglas Berthiaume; Joshua Bekenstein; Michael Berendt; Edward Conrad; Laurie Glimcher; Christopher Kuebler; William Miller; JoAnn Reed; and Thomas Salice.

Bruker's shareholders have re-elected its class 1 directors to serve until the company's 2016 shareholder meeting, including Wolf-Dieter Emmerich; Brenda Furlong; Frank Laukien; and Richard Packer.

Eric Olivares is clinical NGS R&D lead at InVitae. He is the founder of SEQAnswers and was a staff scientist at Pacific Biosciences from 2008-2011. He was also a senior scientist at Invitrogen and a scientific writer/marketing consultant at System Biosciences.

DxInsights, a non-profit, independent diagnostics education organization, has appointed Ethan Knowlden as executive director.

Knowlden was previously with Novartis Vaccines and Diagnostics, and most recently served as vice president, business development and licensing, and corporate counsel for the diagnostics unit.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.